Risk stratifikation for progressive multifocal leukencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status - Sandrock, A; Hotermans, C; Richman, S (Neurology, 2011)
P03.248